CRISPR-Based Therapy for Hereditary Angioedema.

Name: Αlpha¹ Rigor Record — CRISPR-Based Therapy for Hereditary Angioedema.
Item: CRISPR-Based Therapy for Hereditary Angioedema.
Rating: 96
Author: Αlpha¹

Cohn DM, Gurugama P, Magerl M, Katelaris CH, Launay D, Bouillet L, Petersen RS, Lindsay K, Aygören-Pürsün E, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Abdelhady AM, Lebwohl D, Longhurst HJ

Paper source

Read full text

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 5 high issues for “CRISPR-Based Therapy for Hereditary Angioedema.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsOverstated claim ×2−1★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
No data or code availability links were detected to verify.

Problems surfaced2 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 2 randomized controlled trial of an in vivo CRISPR therapy for hereditary angioedema, with strong scientific premise, adequate design, and transparent reporting. The main weaknesses are the lack of a formal power analysis, incomplete description of randomization and statistical software, and a vague data sharing statement. The claim of 'functional cure' is somewhat overstated given the small sample and short follow-up.

Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification component checked 0 tests (none were machine-verifiable), so statistical correctness is not confirmed beyond the reported model. The claim audit flagged two overstatements.

4 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Reporting

Eight Dimensions7 pass · 1 warn

The introduction describes the pathophysiology of hereditary angioedema, the role of plasma kallikrein, and prior evidence that kallikrein inhibition reduces attacks. It also cites the phase 1 results of this same trial, providing a direct rationale for the phase 2 doses. Limitations of prior treatments (lifelong administration) are noted, and the premise is logically linked to the study objectives.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific rationale for targeting KLKB1 with NTLA-2002, citing prior clinical and preclinical evidence.

Evidence

direct quote[Introduction, paragraph 2]

“Plasma kallikrein is clinically validated as a therapeutic target, with kallikrein inhibitors approved for long-term prophylaxis.”